Literature DB >> 30116057

EMA and FDA prune the checkpoint inhibitor treatment landscape.

Min Yuen Teo1, Jonathan E Rosenberg2.   

Abstract

Year:  2018        PMID： 30116057     DOI： 10.1038/s41585-018-0074-1

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  3 in total

Review 1.  The emerging role of antibody-drug conjugates in urothelial carcinoma.

Authors:  Michael Lattanzi; Jonathan E Rosenberg
Journal:  Expert Rev Anticancer Ther       Date:  2020-07-21       Impact factor: 4.512

Review 2.  Molecular and histopathology directed therapy for advanced bladder cancer.

Authors:  Constantine Alifrangis; Ursula McGovern; Alex Freeman; Thomas Powles; Mark Linch
Journal:  Nat Rev Urol       Date:  2019-07-09       Impact factor: 14.432

3.  PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers.

Authors:  Eva Compérat; André Oszwald; Gabriel Wasinger; Justine Wacquet; Morgan Rouprêt; Olivier Cussenot
Journal:  World J Urol       Date:  2021-09-13       Impact factor: 4.226
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.